Immutep (IMMP) announces positive data from investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA and chemotherapy for first-line treatment ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Investor's Business Daily on MSN2h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...
According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback